MREO vs. SMMT, GLPG, ZLAB, PTGX, KROS, EVO, SNDX, NAMS, HRMY, and GPCR
Should you be buying Mereo BioPharma Group stock or one of its competitors? The main competitors of Mereo BioPharma Group include Summit Therapeutics (SMMT), Galapagos (GLPG), Zai Lab (ZLAB), Protagonist Therapeutics (PTGX), Keros Therapeutics (KROS), Evotec (EVO), Syndax Pharmaceuticals (SNDX), NewAmsterdam Pharma (NAMS), Harmony Biosciences (HRMY), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical preparations" industry.
Mereo BioPharma Group (NASDAQ:MREO) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, community ranking, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.
In the previous week, Summit Therapeutics had 11 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 16 mentions for Summit Therapeutics and 5 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 0.96 beat Summit Therapeutics' score of 0.60 indicating that Mereo BioPharma Group is being referred to more favorably in the media.
Mereo BioPharma Group's return on equity of 0.00% beat Summit Therapeutics' return on equity.
Mereo BioPharma Group has higher revenue and earnings than Summit Therapeutics.
Mereo BioPharma Group presently has a consensus price target of $6.50, indicating a potential upside of 88.41%. Summit Therapeutics has a consensus price target of $10.50, indicating a potential upside of 20.90%. Given Mereo BioPharma Group's higher probable upside, analysts plainly believe Mereo BioPharma Group is more favorable than Summit Therapeutics.
Summit Therapeutics received 252 more outperform votes than Mereo BioPharma Group when rated by MarketBeat users. However, 72.34% of users gave Mereo BioPharma Group an outperform vote while only 57.09% of users gave Summit Therapeutics an outperform vote.
62.8% of Mereo BioPharma Group shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 4.1% of Mereo BioPharma Group shares are held by company insiders. Comparatively, 88.3% of Summit Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Mereo BioPharma Group has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -1.13, suggesting that its stock price is 213% less volatile than the S&P 500.
Summary
Mereo BioPharma Group beats Summit Therapeutics on 9 of the 13 factors compared between the two stocks.
Get Mereo BioPharma Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for MREO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MREO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mereo BioPharma Group Competitors List
Related Companies and Tools
